-+ 0.00%
-+ 0.00%
-+ 0.00%

Outlook Therapeutics Announces Executive Leadership Transition; Russell Trenary Has Stepped Down As The Co's President And CEO, Effective Immediately. Lawrence Kenyon, Executive Vice President, CFO, Has Been Appointed Interim CEO

Benzinga·12/03/2024 21:31:05
Listen to the news

Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that Russell Trenary has stepped down as the Company's President and Chief Executive Officer (CEO), effective immediately. Lawrence Kenyon, Executive Vice President, Chief Financial Officer and member of the board of directors, has been appointed Interim CEO.